The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Sugemalimab, aumolertinib show clinical benefit in NSCLC, r/r ENKTL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Data from pivotal trials of sugemalimab, a PD-L1 inhibitor, and aumolertinib, a third-generation EGFR-tyrosine kinase inhibitor, demonstrated the potential clinical benefit of these investigational medicines in non-small cell lung cancer and of sugemalimab in relapsed or refractory extranodal natural killer/T-cell lymphoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

CHMP adopts positive opinion for Adcetris + ECADD for newly diagnosed stage IIb/III/IV Hodgkin lymphoma

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the extension of the marketing authorization of Adcetris (brentuximab vedotin) and recommended its approval in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone, a chemotherapy regimen, in adult patients with newly diagnosed stage 2b with risk factors/3/4 Hodgkin lymphoma.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account